GOLD 2025 highlights new pathways and advanced COPD therapies like ensifentrine and dupilumab to reduce exacerbations and address emerging COPD phenotypes.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Although interstitial lung disease typically develops early in systemic sclerosis, a study of 969 patients revealed that ILD presenting after 7 years of disease showed identical progression rates and severity patterns as early-onset cases, challenging traditional monitoring assumptions.
Despite increased scrutiny during COVID-19, spreading misinformation to the public accounted for just 0.1% of all medical board disciplinary actions - exponentially lower than traditional offenses like negligence (28.7%) and inappropriate prescribing (13.5%).